Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: What thoracic surgeons should know

Isabelle Opitz, Raphael Bueno, Eric Lim, Harvey Pass, Ugo Pastorino, Mattia Boeri, Gaetano Rocco

Research output: Contribution to journalArticlepeer-review

Abstract

Today, molecular-profile-directed therapy is a guiding principle of modern thoracic oncology. The knowledge of new biomolecular technology applied to the diagnosis, prognosis, and treatment of lung cancer and mesothelioma should be part of the 21st century thoracic surgeons' professional competence. The European Society of Thoracic Surgeons (ESTS) Biology Club aims at providing a comprehensive insight into the basic biology of the diseases we are treating. During the 2013 ESTS Annual Meeting, different experts of the field presented the current knowledge about diagnostic and prognostic biomarkers in malignant pleural mesothelioma including new perspectives as well as the role and potential application of microRNA and genomic sequencing for lung cancer, which are summarized in the present article.

Original languageEnglish
Article numberezu048
Pages (from-to)602-606
Number of pages5
JournalEuropean Journal of Cardio-thoracic Surgery
Volume46
Issue number4
DOIs
Publication statusPublished - Oct 1 2014

Keywords

  • Biomarker
  • Genomic sequencing
  • Lung cancer
  • Malignant pleural mesothelioma
  • microRNAs

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: What thoracic surgeons should know'. Together they form a unique fingerprint.

Cite this